Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2019
Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2019
SUMMARY
Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2019, outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Adenosine Receptor A3 (ADORA3) - The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediates a sustained cardioprotective function during cardiac ischemia. It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 2, 4, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules respectively.
Report covers products from therapy areas Gastrointestinal, Immunology, Metabolic Disorders, Ophthalmology, Genito Urinary System And Sex Hormones, Male Health, Central Nervous System, Musculoskeletal Disorders, Oncology, Respiratory and Women's Health which include indications Glaucoma, Non-Alcoholic Steatohepatitis (NASH), Diabetic Nephropathy, Kidney Fibrosis, Arthritis, Chemotherapy Induced Pain, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Erectile Dysfunction, Female Sexual Dysfunction, Hepatocellular Carcinoma, Inflammation, Male Sexual Dysfunction, Melanoma, Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis, Rheumatoid Arthritis and Ulcerative Colitis.
Furthermore, this report also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2019, outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Adenosine Receptor A3 (ADORA3) - The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediates a sustained cardioprotective function during cardiac ischemia. It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 2, 4, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules respectively.
Report covers products from therapy areas Gastrointestinal, Immunology, Metabolic Disorders, Ophthalmology, Genito Urinary System And Sex Hormones, Male Health, Central Nervous System, Musculoskeletal Disorders, Oncology, Respiratory and Women's Health which include indications Glaucoma, Non-Alcoholic Steatohepatitis (NASH), Diabetic Nephropathy, Kidney Fibrosis, Arthritis, Chemotherapy Induced Pain, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Erectile Dysfunction, Female Sexual Dysfunction, Hepatocellular Carcinoma, Inflammation, Male Sexual Dysfunction, Melanoma, Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis, Rheumatoid Arthritis and Ulcerative Colitis.
Furthermore, this report also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)
- The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Adenosine Receptor A3 (ADORA3) - Overview
Adenosine Receptor A3 (ADORA3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development
Acorn Biomedical Inc
BioIntervene Inc
Can-Fite BioPharma Ltd
Future Medicine Co Ltd
Palo BioFarma SL
Adenosine Receptor A3 (ADORA3) - Drug Profiles
ACN-1052 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-1888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-2698 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
namodenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-1650 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piclidenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ADORA3 for Chronic Obstructive Pulmonary Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ADORA3 for Kidney Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adenosine Receptor A3 (ADORA3) - Dormant Products
Adenosine Receptor A3 (ADORA3) - Discontinued Products
Adenosine Receptor A3 (ADORA3) - Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Can-Fite completes 50% patient enrollment in its phase III Psoriasis Trial
Dec 05, 2019: Can-Fite to attend BioFIT 2019 Conference in Europe with focus on partnering meetings for Namodenoson in NASH
Nov 19, 2019: Can-Fite granted patents for its sexual dysfunction drug
Nov 11, 2019: Can-Fite granted U.S. Patent for piclidenoson in the treatment of osteoarthritis, positioning this indication for animal health market
Nov 04, 2019: Can-Fite initiates compassionate use program for namodenoson in the treatment of liver cancer, enrolls and treats patients
Oct 31, 2019: U.S. FDA agreed with Can-Fite’s proposed pivotal phase III trial design to support a new drug application submission and approval of Namodenoson in the treatment of Liver Cancer
Oct 17, 2019: Can-Fite and Gebro Pharma holding European Conference on development & commercialization of phase III drug candidate Piclidenoson in the treatment of Rheumatoid Arthritis
Oct 15, 2019: Can-Fite completes patient enrollment in phase II NASH study of Namodenoson
Oct 10, 2019: Can Fite announces publication of Namodenoson NASH mechanism of action in International Journal of Molecular Medicine
Sep 23, 2019: Can-Fite presents new data on the treatment of advanced liver cancer with Namodenoson at the ILCA Conference
Sep 23, 2019: Can-Fite presents new data on the treatment of advanced liver cancer with Namodenoson at the ILCA Conference
Aug 06, 2019: Can-Fite to treat Advanced Liver Cancer patients with Namodenoson under compassionate use setting in Israel
Jun 04, 2019: Can-Fite Participating in One-on-One Partnering Meeting for Piclidenoson at the BIO International Convention on June 3-6, 2019
Jun 04, 2019: Can-Fite Participating in One-on-One Partnering Meetings at the BIO International Convention on June 3-6, 2019
Jun 03, 2019: Findings from Can-Fites phase II Liver Cancer Study were presented at ASCO Annual Meeting Late-Breaking Session
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Adenosine Receptor A3 (ADORA3) - Overview
Adenosine Receptor A3 (ADORA3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development
Acorn Biomedical Inc
BioIntervene Inc
Can-Fite BioPharma Ltd
Future Medicine Co Ltd
Palo BioFarma SL
Adenosine Receptor A3 (ADORA3) - Drug Profiles
ACN-1052 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-1888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-2698 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
namodenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-1650 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piclidenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ADORA3 for Chronic Obstructive Pulmonary Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ADORA3 for Kidney Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adenosine Receptor A3 (ADORA3) - Dormant Products
Adenosine Receptor A3 (ADORA3) - Discontinued Products
Adenosine Receptor A3 (ADORA3) - Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Can-Fite completes 50% patient enrollment in its phase III Psoriasis Trial
Dec 05, 2019: Can-Fite to attend BioFIT 2019 Conference in Europe with focus on partnering meetings for Namodenoson in NASH
Nov 19, 2019: Can-Fite granted patents for its sexual dysfunction drug
Nov 11, 2019: Can-Fite granted U.S. Patent for piclidenoson in the treatment of osteoarthritis, positioning this indication for animal health market
Nov 04, 2019: Can-Fite initiates compassionate use program for namodenoson in the treatment of liver cancer, enrolls and treats patients
Oct 31, 2019: U.S. FDA agreed with Can-Fite’s proposed pivotal phase III trial design to support a new drug application submission and approval of Namodenoson in the treatment of Liver Cancer
Oct 17, 2019: Can-Fite and Gebro Pharma holding European Conference on development & commercialization of phase III drug candidate Piclidenoson in the treatment of Rheumatoid Arthritis
Oct 15, 2019: Can-Fite completes patient enrollment in phase II NASH study of Namodenoson
Oct 10, 2019: Can Fite announces publication of Namodenoson NASH mechanism of action in International Journal of Molecular Medicine
Sep 23, 2019: Can-Fite presents new data on the treatment of advanced liver cancer with Namodenoson at the ILCA Conference
Sep 23, 2019: Can-Fite presents new data on the treatment of advanced liver cancer with Namodenoson at the ILCA Conference
Aug 06, 2019: Can-Fite to treat Advanced Liver Cancer patients with Namodenoson under compassionate use setting in Israel
Jun 04, 2019: Can-Fite Participating in One-on-One Partnering Meeting for Piclidenoson at the BIO International Convention on June 3-6, 2019
Jun 04, 2019: Can-Fite Participating in One-on-One Partnering Meetings at the BIO International Convention on June 3-6, 2019
Jun 03, 2019: Findings from Can-Fites phase II Liver Cancer Study were presented at ASCO Annual Meeting Late-Breaking Session
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Acorn Biomedical Inc, H2 2019
Pipeline by BioIntervene Inc, H2 2019
Pipeline by Can-Fite BioPharma Ltd, H2 2019
Pipeline by Future Medicine Co Ltd, H2 2019
Pipeline by Palo BioFarma SL, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Acorn Biomedical Inc, H2 2019
Pipeline by BioIntervene Inc, H2 2019
Pipeline by Can-Fite BioPharma Ltd, H2 2019
Pipeline by Future Medicine Co Ltd, H2 2019
Pipeline by Palo BioFarma SL, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
Acorn Biomedical Inc
BioIntervene Inc
Can-Fite BioPharma Ltd
Future Medicine Co Ltd
Palo BioFarma SL
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
Acorn Biomedical Inc
BioIntervene Inc
Can-Fite BioPharma Ltd
Future Medicine Co Ltd
Palo BioFarma SL
